Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BETA Technologies, Inc.BETA · Entity 1930 | Director | June 11, 2026 | June 12, 2026 |
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director · Chairperson & CEO | October 13, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BETA Technologies, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 8,213 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 7,142 · Balance 8,213 |
UNITED THERAPEUTICS Corp
Report date October 13, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 333,943 |
Reported balance
After 2026-10-13 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-10-13 · Exercise / conversion · Acquired 9,500 · Balance 333,943 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 333,304 |
Reported balance
After 2026-10-13 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-10-13 · Sale · Disposed 639 · Balance 333,304 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 330,964 |
Reported balance
After 2026-10-13 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-10-13 · Sale · Disposed 2,340 · Balance 330,964 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 329,472 |
Reported balance
After 2026-10-13 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-10-13 · Sale · Disposed 1,492 · Balance 329,472 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 327,965 |
Reported balance
After 2026-10-13 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2026-10-13 · Sale · Disposed 1,507 · Balance 327,965 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 326,513 |
Reported balance
After 2026-10-13 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2026-10-13 · Sale · Disposed 1,452 · Balance 326,513 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 325,883 |
Reported balance
After 2026-10-13 transaction · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · 2026-10-13 · Sale · Disposed 630 · Balance 325,883 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 325,185 |
Reported balance
After 2026-10-13 transaction · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · 2026-10-13 · Sale · Disposed 698 · Balance 325,185 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,683 |
Reported balance
After 2026-10-13 transaction · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · 2026-10-13 · Sale · Disposed 502 · Balance 324,683 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,523 |
Reported balance
After 2026-10-13 transaction · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · 2026-10-13 · Sale · Disposed 160 · Balance 324,523 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,443 |
Reported balance
After 2026-10-13 transaction · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · 2026-10-13 · Sale · Disposed 80 · Balance 324,443 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 249,108 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 249,108 F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 45,596 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 45,596 F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 8,902 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 8,902 F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.76 · Expires 2027-03-15 | Indirectby Trust | 242,910 |
Reported balance
After 2026-10-13 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-10-13 · Exercise / conversion · Disposed 9,500 · Balance 242,910 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023. F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Direct | 40,513 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 40,513 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 166 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 166 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2024 Filed Aug 2, 2024 21:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 224 | $321.70 | $72,061.00 |
DisclosureSEC source: 0001415889-24-020646 · form4-08022024_090853.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 776 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F9 · price: This transaction was executed in multiple trades at prices ranging from $321.44 to $321.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 21:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 551 | $320.88 | $176,806.86 |
DisclosureSEC source: 0001415889-24-020646 · form4-08022024_090853.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F8 · price: This transaction was executed in multiple trades at prices ranging from $320.40 to $321.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 21:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 220 | $319.55 | $70,300.91 |
DisclosureSEC source: 0001415889-24-020646 · form4-08022024_090853.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,551 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $319.08 to $319.965. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 21:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 383 | $318.08 | $121,824.68 |
DisclosureSEC source: 0001415889-24-020646 · form4-08022024_090853.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,771 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $317.93 to $318.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 21:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 491 | $317.49 | $155,887.25 |
DisclosureSEC source: 0001415889-24-020646 · form4-08022024_090853.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $316.885 to $317.785. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 21:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 222 | $314.97 | $69,922.96 |
DisclosureSEC source: 0001415889-24-020646 · form4-08022024_090853.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,645 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $314.765 to $315.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 21:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 554 | $314.03 | $173,973.67 |
DisclosureSEC source: 0001415889-24-020646 · form4-08022024_090853.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,867 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $313.58 to $314.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 21:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 309 | $313.05 | $96,732.45 |
DisclosureSEC source: 0001415889-24-020646 · form4-08022024_090853.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,421 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $312.525 to $313.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 21:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,600 | $129.49 | $466,164.00 |
DisclosureSEC source: 0001415889-24-020646 · form4-08022024_090853.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,600 | $0.00 Strike: $129.49 | $0.00 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · derivative · entry 25 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,069 Underlying: Common Stock · 3,600 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 142 | $341.76 | $48,530.47 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 17 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F15 · price: This transaction was executed in multiple trades at prices ranging from $341.065 to $341.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 138 | $340.03 | $46,923.99 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 16 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 272 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F14 · price: This transaction was executed in multiple trades at prices ranging from $339.955 to $340.805. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 453 | $338.98 | $153,559.30 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 15 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 410 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F13 · price: This transaction was executed in multiple trades at prices ranging from $338.465 to $339.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 822 | $337.75 | $277,632.23 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 14 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 863 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F12 · price: This transaction was executed in multiple trades at prices ranging from $337.245 to $338.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,432 | $336.81 | $482,305.76 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 13 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,685 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F11 · price: This transaction was executed in multiple trades at prices ranging from $336.225 to $337.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 515 | $335.73 | $172,899.51 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,117 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F10 · price: This transaction was executed in multiple trades at prices ranging from $335.205 to $336.165. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 98 | $334.48 | $32,779.00 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,632 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F9 · price: This transaction was executed in multiple trades at prices ranging from $334.155 to $334.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,600 | $129.49 | $466,164.00 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,600 | $0.00 Strike: $129.49 | $0.00 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · derivative · entry 24 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,669 Underlying: Common Stock · 3,600 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 125 | $340.29 | $42,535.63 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 421 | $339.54 | $142,947.52 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 255 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F8 · price: This transaction was executed in multiple trades at prices ranging from $339.05 to $339.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 247 | $337.90 | $83,460.73 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 676 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $337.67 to $338.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 335 | $337.24 | $112,974.29 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 923 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $336.615 to $337.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 452 | $335.81 | $151,788.20 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,258 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $335.56 to $336.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 802 | $334.84 | $268,538.71 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,710 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $334.425 to $335.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 989 | $333.85 | $330,179.13 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,512 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $333.385 to $334.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 229 | $332.67 | $76,180.90 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,501 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $332.315 to $333.155. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,600 | $129.49 | $466,164.00 |
DisclosureSEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| July 26, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,600 | $0.00 Strike: $129.49 | $0.00 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · derivative · entry 24 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,269 Underlying: Common Stock · 3,600 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| July 26, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 950 | $339.78 | $322,794.80 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 16 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F15 · price: This transaction was executed in multiple trades at prices ranging from $339.57 to $340.135. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 26, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,115 | $339.29 | $378,304.56 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 15 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,080 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F14 · price: This transaction was executed in multiple trades at prices ranging from $338.57 to $339.565. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 26, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 723 | $337.91 | $244,306.33 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 14 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,195 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F13 · price: This transaction was executed in multiple trades at prices ranging from $337.38 to $338.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 26, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 812 | $336.95 | $273,605.19 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 13 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,918 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F12 · price: This transaction was executed in multiple trades at prices ranging from $336.37 to $337.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 26, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,600 | $129.49 | $466,164.00 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,600 | $0.00 Strike: $129.49 | $0.00 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · derivative · entry 23 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,869 Underlying: Common Stock · 3,600 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 90 | $343.79 | $30,940.98 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F11 · price: This transaction was executed in multiple trades at prices ranging from $343.435 to $343.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 244 | $342.53 | $83,578.37 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F10 · price: This transaction was executed in multiple trades at prices ranging from $342.32 to $343.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 724 | $341.60 | $247,315.00 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F9 · price: This transaction was executed in multiple trades at prices ranging from $341.22 to $342.095. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 531 | $340.39 | $180,744.75 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,188 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F8 · price: This transaction was executed in multiple trades at prices ranging from $340.15 to $340.825. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 297 | $339.80 | $100,919.65 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,719 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $339.66 to $340.065. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 5 | $339.22 | $1,696.09 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,016 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $338.63 to $339.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 214 | $337.79 | $72,285.99 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,021 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $337.475 to $338.075. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 776 | $336.72 | $261,292.55 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,235 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $336.375 to $337.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 589 | $335.85 | $197,814.88 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,011 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $335.36 to $336.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 130 | $333.93 | $43,410.55 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,600 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $333.73 to $334.015. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,600 | $129.49 | $466,164.00 |
DisclosureSEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| July 24, 2024 Filed Jul 25, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,600 | $0.00 Strike: $129.49 | $0.00 |
DisclosureSEC source: 0001415889-24-020102 · form4-07252024_040701.xml · derivative · entry 22 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,469 Underlying: Common Stock · 3,600 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. Read SEC document |
| July 24, 2024 Filed Jul 25, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 163 | $337.09 | $54,945.49 |
DisclosureSEC source: 0001415889-24-020102 · form4-07252024_040701.xml · nonDerivative · entry 14 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F11 · price: This transaction was executed in multiple trades at prices ranging from $336.59 to $337.525. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 24, 2024 Filed Jul 25, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 696 | $335.99 | $233,850.99 |
DisclosureSEC source: 0001415889-24-020102 · form4-07252024_040701.xml · nonDerivative · entry 13 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 293 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F10 · price: This transaction was executed in multiple trades at prices ranging from $335.47 to $336.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 24, 2024 Filed Jul 25, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 744 | $334.77 | $249,066.28 |
DisclosureSEC source: 0001415889-24-020102 · form4-07252024_040701.xml · nonDerivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 989 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024. F9 · price: This transaction was executed in multiple trades at prices ranging from $334.38 to $335.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.